This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lynch, J. J. Articles by Grossman, W. Search for Related Content PubMed PubMed Citation Articles by Lynch, J. J., Jr. Articles by Grossman, W.

EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction

Joseph J. Lynch, Jr., PhD^*, Gary L. Stump, BS^*, Audrey A. Wallace, BS^*, Carla A. Painter, BS^*, Justina M. Thomas, BS, Sandra E. Kusma, BS, Robert J. Gould, PhD^* and William Grossman, MD, FACC^,1

^* Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA
Department of Safety Assessment, Merck Research Laboratories, West Point, Pennsylvania, USA
Department of Clinical Cardiovascular Research, Merck Research Laboratories, West Point, Pennsylvania, USA

View larger version (20K): [in a new window]   Figure 1 Survival of losartan (n = 8; 1 mg/kg IV bolus + 0.03 mg/kg/min continuous IV infusion), EXP3174 (n = 8; 0.1 mg/kg IV bolus + 0.01 mg/kg/min continuous IV infusion), captopril (n = 10; 1 mg/kg IV bolus + 0.5 mg/kg/h continuous IV infusion) and vehicle-treated (n = 9) dogs with previous anterior myocardial infarction expressed as a function of time after onset of thrombotically induced acute posterolateral myocardial ischemia.